Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Non-Current Assets (2020 - 2025)

Historic Non-Current Assets for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $32.9 million.

  • Tarsus Pharmaceuticals' Non-Current Assets rose 7128.19% to $32.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.7 million, marking a year-over-year increase of 8243.34%. This contributed to the annual value of $20.3 million for FY2024, which is 11673.08% up from last year.
  • As of Q3 2025, Tarsus Pharmaceuticals' Non-Current Assets stood at $32.9 million, which was up 7128.19% from $20.6 million recorded in Q2 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' Non-Current Assets peaked at $32.9 million during Q3 2025, and registered a low of $2.4 million during Q3 2022.
  • Moreover, its 5-year median value for Non-Current Assets was $5.5 million (2023), whereas its average is $9.7 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first tumbled by 2818.89% in 2022, then surged by 27934.65% in 2023.
  • Over the past 5 years, Tarsus Pharmaceuticals' Non-Current Assets (Quarter) stood at $3.0 million in 2021, then fell by 15.8% to $2.5 million in 2022, then skyrocketed by 276.21% to $9.4 million in 2023, then surged by 116.73% to $20.3 million in 2024, then skyrocketed by 61.97% to $32.9 million in 2025.
  • Its last three reported values are $32.9 million in Q3 2025, $20.6 million for Q2 2025, and $20.0 million during Q1 2025.